Format

Send to

Choose Destination
Int J Mol Sci. 2015 Jun 29;16(7):14669-76. doi: 10.3390/ijms160714669.

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.

Author information

1
Department of Neurology, University of Ulm, Ulm 89081, Germany. rau.daniela@gmx.de.
2
Neuropoint Patient Academy, Neurological Practice Center, Ulm 89073, Germany. lang@neurologie-ulm.de.
3
Department of Neurology, Military Hospital, Ulm 89081, Germany. AndreasHarth@bundeswehr.org.
4
Department of Neurology, Klinikum Augsburg, Augsburg 86156, Germany. Markus.naumann@klinikum-augsburg.de.
5
Department of Neurology, Military Hospital, Ulm 89081, Germany. frankweber@bundeswehr.org.
6
Department of Neurology, University of Ulm, Ulm 89081, Germany. Hayrettin.Tumani@rku.de.
7
Department of Neurology, Klinikum Augsburg, Augsburg 86156, Germany. antonios.bayas@klinikum-augsburg.de.

Abstract

Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication.

KEYWORDS:

Listeria monocytogenes; alemtuzumab; meningitis; multiple sclerosis

PMID:
26132570
PMCID:
PMC4519865
DOI:
10.3390/ijms160714669
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center